Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial ...

Idorsia Ltd is reaching out for more - we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...

In a report released on February 26, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), ...

Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond d ...

In a report released on February 12, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), with a price target of CHF2.20. Leverage the power of ...

Idorsia Ltd (SIX: IDIA) today announced that it has published the agenda items for the bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025 ...

Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025 ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for ...